Business
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership ExperienceANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members. “We are thrilled to welcome Craig to our Board of Directors. With more than two decades of bio
About this update from Esperion Therapeutics, Inc.
[{"type":"image","alt":"Esperion Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Esperion Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l5dS5p4arlgcAzQpBUpJMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21","width":300,"height":94}},"lazy":false},{"type":"text","content":"Brings More Than Twenty Years of Biopharmaceutical Leadership Experience","length":72,"tagName":"p"},{"type":"text","content":"ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members.","length":333,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug development. His deep understanding of pharmaceutical commercialization and clinical development aligns perfectly with our mission to deliver life-saving solutions to patients worldwide. We look forward to his contributions as we enter our next phase of growth and innovation,” stated Sheldon Koenig, President and CEO of Esperion.","length":690,"tagName":"p"},{"type":"text","content":""I am honored to join the Board of Esperion, a company at the forefront of transforming cardiovascular disease prevention. With cardiovascular conditions remaining the leading cause of death globally, the need for innovative, proactive solutions has never been greater. I look forward to working alongside this exceptional team to help guide strategic decisions and accelerate the development of impactful, science-driven approaches that can improve and extend lives," said Mr. Thompson.","length":497,"tagName":"p"},{"type":"text","content":"Mr. Thompso...